Full-Time

Associate Director

Immunoassay Development

Vaxcyte

Vaxcyte

501-1,000 employees

Develops broad-spectrum vaccines for bacterial infections

Compensation Overview

$190k - $220k/yr

+ Equity component

San Carlos, CA, USA

In Person

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
GMP
Biochemistry

Get referred to Vaxcyte

See people who can refer or advise you

Requirements
  • A PhD in Biochemistry, Immunology, Analytical Chemistry, Biological Sciences, or a related discipline with at least 7 years of relevant biopharmaceutical industry experience, or an M.S. in a related discipline with at least 10 years of relevant biopharmaceutical industry experience; other combinations of education and experience may be considered.
  • Significant hands-on laboratory experience developing, optimizing, troubleshooting, transferring, validating, lifecycle-supporting, and executing immunoassays in vaccine CMC, biologics analytical development, QC, ASAT, or other regulated analytical environments.
  • Expertise in immunoassay method development, including assay format selection, antibody reagent strategy, reagent screening, reagent evaluation and selection, sample preparation, assay optimization, robustness assessment, qualification, validation readiness, and lifecycle management.
  • Strong technical experience with ligand-binding immunoassay platforms such as ELISA, MSD, Luminex, or other relevant immunoassay technologies.
  • Ability to troubleshoot complex immunoassay performance trends using structured, data-driven root-cause analysis approaches.
  • Experience evaluating alternative or innovative immunoassay platforms and translating experimental data into method development recommendations.
  • Experience developing or improving potency, antigenicity, identity, or impurity assays supporting vaccine or biologics release, stability, comparability, process development, method transfer, validation, routine testing, or regulatory submissions.
  • Experience supporting outsourced immunoassay activities, including interactions with CROs, CDMOs, contract testing laboratories, reagent vendors, or external technology partners.
  • Ability to support daily laboratory operations, including study planning, sample and reagent readiness, testing prioritization, data review, documentation, and technical troubleshooting.
  • Understanding of protein chemistry, polysaccharide chemistry, conjugation chemistry, antigen structure, antibody-antigen interactions, and biological sample matrix effects as applied to vaccine analytical development.
  • Working knowledge of global regulatory expectations for analytical methods supporting vaccines and biologics, including FDA, EMA, ICH, and GMP expectations.
  • Ability to mentor, train, and provide technical guidance to laboratory scientists.
  • Ability to manage multiple laboratory studies, technical workstreams, outsourced activities, validation-support activities, routine testing needs, timelines, and deliverables in a fast-paced, matrixed environment.
  • Scientific judgment and ability to make sound technical recommendations when working with incomplete, complex, or conflicting data.
  • Written and verbal communication skills sufficient to clearly communicate technical concepts, study results, risks, and recommendations to cross-functional stakeholders and external partners.
  • Commitment to data integrity, documentation quality, scientific excellence, accountability, and continuous improvement.
Responsibilities
  • Contribute to establishing and growing the Immunoassay Development Capability within Global Analytical Development, emphasizing hands-on immunoassay development, troubleshooting, method optimization, platform evaluation, routine testing, outsourcing support, validation readiness, and control strategy execution.
  • Engage daily in laboratory operations, including experimental planning, assay execution, sample and reagent readiness, study scheduling, instrument and workflow coordination, data review, documentation, and hands-on technical support.
  • Lead and directly execute laboratory studies for immunoassay development, optimization, troubleshooting, qualification support, method transfer, validation support, lifecycle management, and routine analytical testing.
  • Provide hands-on technical leadership for immunoassays supporting potency, antigenicity, identity, impurity, characterization, comparability, release, and stability needs for complex conjugated vaccines and other vaccine pipeline programs.
  • Design, execute, and interpret experiments evaluating assay format, sample preparation, reagent strategy, plate or bead configuration, signal detection, curve behavior, recovery, precision, specificity, robustness, and system suitability.
  • Troubleshoot immunoassay performance trends using structured, data-driven root-cause analysis and clear experimental plans.
  • Support development of fit-for-purpose immunoassay methods from concept through optimization, qualification readiness, transfer readiness, validation readiness, and lifecycle strategy.
  • Assess alternative and innovative immunoassay approaches, platforms, and formats to support assay modernization, multiplexing, throughput, sensitivity, specificity, robustness, and long-term control strategy.
  • Support comparative evaluation of immunoassay technologies, including ELISA, MSD, Luminex, and other ligand-binding assay formats.
  • Perform and oversee routine analytical testing, including development-stage testing, characterization testing, platform evaluation studies, method bridging, comparability support, reagent qualification, and non-GMP or GMP-supporting analytical activities.
  • Support outsourced immunoassay activities, including technical scope definition, study design review, data review, vendor communication, and deliverable tracking.
  • Support immunoassay method validation activities, including protocol input, acceptance criteria, data interpretation, deviation support, and final report review.
  • Partner with internal and external subject matter experts to understand assay design, critical reagents, reference materials, method performance attributes, and control strategy needs.
  • Support QC and ASAT teams with technical questions related to release, stability, comparability, PPQ, method transfer, validation readiness, and commercial readiness.
  • Contribute to immunoassay analytical control strategies covering critical reagent strategy, reference material strategy, sample preparation, assay controls, system suitability, bridging plans, trending, and lifecycle monitoring.
  • Manage assigned immunoassay development, troubleshooting, outsourcing, validation-support, platform evaluation, and routine testing activities, including study planning, resource coordination, timeline management, data review, deliverable tracking, and risk escalation.
  • Mentor and provide technical guidance to laboratory scientists on experimental design, assay execution, data interpretation, troubleshooting, documentation, and good laboratory practices.
  • Contribute to regulatory submissions, health authority responses, technical reports, method development reports, validation strategies, comparability packages, platform evaluation summaries, and BLA-supporting documentation.
  • Represent Immunoassay Development in technical project meetings, cross-functional reviews, vendor discussions, and external collaborations as needed.
Desired Qualifications
  • Direct experience with conjugated vaccines, polysaccharide-protein conjugates, multivalent vaccines, or other complex biologics.
  • Hands-on experience with MSD platforms.
  • Hands-on experience with Luminex or other multiplex immunoassay platforms.
  • Experience working in or supporting GMP-regulated analytical environments, including familiarity with method qualification, validation, transfer, change control, deviations, investigations, CAPA, data integrity, and lifecycle management.
  • Experience supporting late-stage development, PPQ readiness, BLA preparation, commercial launch, or lifecycle management of vaccine or biologics programs.
  • Direct experience supporting analytical methods used for GMP release and stability testing.
  • Experience with immunoassay transfer, validation, bridging, comparability, critical reagent qualification, reference material qualification, and long-term method performance monitoring.
  • Experience managing or supporting outsourced immunoassay development, validation, platform evaluation, or routine testing activities with external laboratories or technology partners.
  • Experience developing alternative or next-generation immunoassay methods to strengthen analytical capability and support long-term control strategy.
  • Experience contributing to health authority responses or regulatory submissions on analytical, potency, antigenicity, or immunoassay-related topics.
  • Experience helping build or scale analytical capabilities and laboratory teams within a growing organization.
  • Experience with multivalent or highly complex vaccine programs.
  • Experience with automation, high-throughput immunoassay workflows, multiplex assay design, LIMS, ELN, and digital data analysis tools.

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Get referred to Vaxcyte

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 enrollment completion removed major execution risk across three Phase 3 trials.
  • VAX-A1 entered first-in-human dosing in June 2026, expanding the pipeline beyond pneumococcus.
  • PCV31 adult data could support a BLA submission and U.S. commercial launch in 2027.

What critics are saying

  • OPUS-1 topline data lands in Q4 2026; any miss crushes VAX-31's valuation.
  • June 30, 2026 cash was $2.51 billion, but operating burn stays punishing.
  • VAX-31 failure leaves Vaxcyte a pre-revenue vaccine company with no approved products.

What makes Vaxcyte unique

  • Vaxcyte's XpressCF platform and 31-valent PCV31 target higher serotype coverage than PCV20.
  • OPUS-1, OPUS-2, and OPUS-3 fully enrolled 6,191 adults by August 2026.
  • Thermo Fisher's up to $1 billion U.S. fill-finish deal secures commercial manufacturing capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

1%
Yahoo Finance
Jun 1st, 2026
Vaxcyte completes VAX-31 Phase 3 trial enrollment, shares rise 8.7%

Vaxcyte shares rose 8.7% after completing enrollment for three Phase 3 adult trials of its VAX-31 pneumococcal vaccine candidate and a Phase 2 infant study. The company also announced plans to begin a Phase 1 adult trial for its VAX-A1 Group A Strep programme. The milestone reduces execution risk whilst advancing Vaxcyte's two-pillar strategy targeting both adult and paediatric pneumococcal markets. The company's narrative projects $224.6 million revenue by 2029, representing an earnings increase of approximately $794.7 million from current levels. Some analysts forecast Vaxcyte reaching $424 million revenue by 2029. Key near-term catalysts include OPUS-1 Phase 3 adult data readout, though higher research and manufacturing spending may pressure the company's cash runway before late-stage outcomes are determined.

GlobeNewswire
Apr 7th, 2026
Vaxcyte to present at the 25th Annual Needham Virtual Healthcare Conference.

Vaxcyte to present at the 25th Annual Needham Virtual Healthcare Conference. April 07, 2026 16:05 ET | Source: Vaxcyte, Inc. SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) - Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company's carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company's PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF(R), its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company's system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte's pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com. Jeff Macdonald, Executive Director, Investor Relations Vaxcyte, Inc. 917-371-0940 [email protected]

MJH Life Sciences
Mar 28th, 2026
Vaxcyte announces significant development of first-of-its-kind PCV31.

Vaxcyte announces significant development of first-of-its-kind PCV31. With the OPUS-1, 2, and 3 trials underway, Vax-31 has the potential to become the first pneumococcal vaccine of its kind, demonstrating never-before-seen impacts on disease burden. Vaxcyte recently announced significant progress in the clinical development of VAX-31, its 31-valent pneumococcal conjugate vaccine (PCV31) candidate, according to a news release.[1] As the highest-valent PCV currently under development, VAX-31 is being positioned as a potential best-in-class protection against pneumococcal disease for both adults and infants. "The continued advancement of VAX-31 in adults reflects disciplined execution across our phase 3 clinical program, which was finalized in consultation and alignment with the FDA, as we work toward delivering a best-in-class, next-generation PCV with the potential to set a new standard of care for adults and children," Grant Pickering, CEO and co-founder of Vaxcyte, said in the news release. "In adults, evaluating VAX-31 in settings that reflect real-world vaccination practice, including coadministration with a seasonal influenza vaccine and in individuals with prior pneumococcal vaccination, will provide important insights into how VAX-31 is expected to perform across the adult population." Dosing has commenced in the phase 3 OPUS-2 trial, which evaluates the vaccine's performance when administered concomitantly with seasonal influenza vaccines in pneumococcal-naïve adults 50 years and older. Simultaneously, Vaxcyte completed enrollment for a phase 2 infant dose-finding study, marking a critical step toward addressing the leading cause of vaccine-preventable deaths in children under 5 globally.[1] For pharmacists, who serve as the most accessible members of the health care team, these advancements represent a vital expansion of the tools available to combat infectious disease burden, which saw invasive pneumococcal disease (IPD) incidence nearly double between 2012 and 2024.[2,3] The clinical relevance of VAX-31 is underscored by its design to cover approximately 95% of invasive pneumococcal disease (IPD)-causing serotypes circulating in US adults over 50 years.[1] This broad spectrum is necessary because, despite the efficacy of current options like PCV20 and the recently approved PCV21, the phenomenon of serotype replacement continues to push nonvaccine serotypes into prominence.[3] To provide pharmacists and the FDA with real-world data, the OPUS-2 trial utilizes a randomized, double-blind approach to compare concomitant and sequential administration with flu shots, and the upcoming OPUS-3 study will specifically evaluate VAX-31 in adults who have previously received other pneumococcal vaccines, such as the 23-valent pneumococcal polysaccharide vaccine (PPSV23) or PCV20.[1] The push for higher valency, however, brings technical challenges regarding immunogenicity. Research comparing earlier vaccines like PCV7 and PCV13 with newer PCV15 and PCV20 formulations suggested that increasing the number of polysaccharides can sometimes result in lower antibody responses for common serotypes, according to the Canada Communicable Disease Report.[4] To mitigate this, some pipeline candidates - such as Inventprise's PCV25 - are utilizing innovative hydrazide-polyethylene glycol-hydrazide (Hz-PEG-Hz) linker technology to reduce carrier-induced immune interference.[2] Vaxcyte's own platform similarly aims to maintain robust immune responses while expanding coverage, a necessity as the CDC recently lowered the routine vaccination age to 50 years old.[1,5,6] In the pediatric sector, VAX-31 is designed to protect against approximately 92% of IPD serotypes and 96% of acute otitis media cases in children.[1] This is particularly important because PCVs provide nasal immunity by stimulating antibodies in the nasal mucosa, which prevents colonization and is a feature missing from PPSV23.[6] Furthermore, dosing schedules remain a point of clinical discussion, and the World Health Organization supports a 2+1 schedule for healthy children. However, some data indicates that a 3+1 schedule provides superiority.[4] Vaxcyte's ongoing infant study follows the 4-dose series to ensure maximum protection.[1] As the landscape shifts toward sophisticated platforms like Vaxcyte's cell-free protein synthesis system, the goal remains a serotype-independent vaccine - the holy grail of the pneumococcal vaccine industry.[1,7] Pharmacists can bridge current gaps by using the PneumoRecs VaxAdvisor app to navigate complex guidelines and stay updated on Vaxcyte's expanding pipeline, which also includes candidates for Group A Streptococcus and Shigella.[1,2,5] With Vaxcyte committing up to $1 billion toward US manufacturing, the infrastructure is being set to support these next-generation preventions.[1] "We expect to announce topline data from the ongoing OPUS-1 Phase 3 pivotal, noninferiority trial in the fourth quarter of 2026 and results from these additional Phase 3 adult studies in the first half of 2027, keeping us on track toward a planned Biologics License Application submission," concluded Pickering, according to the release. Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for its. References. 1. Vaxcyte advances adult and infant programs for VAX-31, a potential best-in-class, next-generation pneumococcal conjugate vaccine. News release. Vaxcyte, inc. january 22, 2026. Accessed march 18, 2026. https://www.biospace.com/press-releases/vaxcyte-advances-adult-and-infant-programs-for-vax-31-a-potential-best-in-class-next-generation-pneumococcal-conjugate-vaccine. 2. Nowosielski B. New 25-valent pneumococcal vaccine shows promise in global disease coverage. Drug Topics. March 13, 2026. Accessed march 18, 2026. https://www.drugtopics.com/view/new-25-valent-pneumococcal-vaccine-shows-promise-in-global-disease-coverage. 3. Nowosielski B. Rise in IPD calls for development of more pneumococcal vaccines. Drug Topics. November 17, 2025. Accessed march 18, 2026. https://www.drugtopics.com/view/rise-in-ipd-calls-for-development-of-more-pneumococcal-vaccines. 4. De wals P. PCV13, PCV15 or PCV20: which vaccine is best for children in terms of immunogenicity? Can commun dis rep. 2024 jan 1;50(1-2):35-39. doi: 10.14745/ccdr.v50i12a04. 5. Pneumococcal vaccine recommendations. CDC. February 25, 2026. Accessed march 18, 2026. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html. 6. Katella K. Should i get the pneumococcal vaccine? 5 things to know. Yale medicine. December 12, 2024. Accessed march 18, 2026. https://www.yalemedicine.org/news/should-i-get-the-pneumococcal-vaccine-5-things-to-know. 7. Musher DM, anderson R, feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia (nathan). 2022 sep 25;14(1):5. doi: 10.1186/s41479-022-00097-y. Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Simply Wall St
Mar 8th, 2026
Vaxcyte reports $766M loss and raises $408M in follow-on offering amid widening cash burn

Vaxcyte reported a full-year 2025 net loss of $766.63 million and completed a $408.1 million follow-on equity offering in February 2026. The biotech company also filed an additional $500 million at-the-market programme and a $473.86 million shelf registration for employee stock plans. The funding moves underscore Vaxcyte's reliance on equity financing to support its pneumococcal vaccine pipeline, particularly its OPUS Phase 3 programme for VAX-31. Whilst the capital raises improve funding flexibility, they raise concerns about shareholder dilution and mounting cash burn. Simply Wall St community fair value estimates for Vaxcyte range widely from $10.90 to $109 per share. The company's shares may be trading 35% above fair value despite recent declines, according to the analysis.

Vaxcyte
Feb 3rd, 2026
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Vaxcyte, Inc.

SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share.